Skip to main content
Top
Published in: Journal of NeuroVirology 4/2023

08-06-2023 | Affective Disorder

Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression

Authors: Rong Fu, Hyder Jinnah, J. Lucas Mckay, Andrew H. Miller, Jennifer C. Felger, Eugene W. Farber, Sanjay Sharma, Neil Whicker, Raeanne C. Moore, Donald Franklin, Scott L. Letendre, Albert M. Anderson

Published in: Journal of NeuroVirology | Issue 4/2023

Login to get access

Abstract

Depression is a common illness in people with HIV (PWH) and is associated with substantial morbidity and mortality. The mechanisms that underpin depression in PWH remain incompletely elucidated, and more research is therefore needed to develop effective treatments. One hypothesis is that neurotransmitter levels may be altered. These levels could be influenced by the chronic inflammation and viral persistence that occurs in PWH. We examined a panel of cerebrospinal fluid (CSF) neurotransmitters in PWH on suppressive antiretroviral therapy (ART), many of whom had a current depression diagnosis. CSF monoamine neurotransmitters and their metabolites were measured from participants in studies at the Emory Center for AIDS Research (CFAR). Only participants on stable ART with suppressed HIV RNA from both plasma and CSF were analyzed. Neurotransmitter levels were measured with high-performance liquid chromatography (HPLC). Neurotransmitters and their metabolites included dopamine (DA), homovanillic acid (HVA, a major metabolite of dopamine), serotonin (5-HT), 5-hydroxyindole-3-acetic acid (5-HIAA, a major metabolite of serotonin), and 4-hydroxy-3-methoxyphenylglycol (MHPG, a major metabolite of norepinephrine). Multivariable logistic regression was used to evaluate factors associated with depression. There were 79 PWH with plasma and CSF HIV RNA levels < 200 copies/mL at the time of the visit, and 25 (31.6%) carried a current diagnosis of depression. Participants with depression were significantly older (median age 53 years versus 47 years, P = 0.014) and were significantly less likely to be African American (48.0% versus 77.8%, P = 0.008). Participants with depression had significantly lower dopamine levels (median 0.49 ng/mL versus 0.62 ng/mL, P = 0.03) and significantly lower 5-HIAA levels (median 12.57 ng/mL versus 15.41 ng/mL, P = 0.015). Dopamine and 5-HIAA were highly correlated. In the multivariable logistic regression models, lower 5-HIAA was significantly associated with the depression diagnosis when accounting for other significant demographic factors. The associations between lower 5-HIAA, lower dopamine, and depression in PWH suggest that altered neurotransmission may contribute to these comorbid conditions. However, the effects of antidepressants on neurotransmitters cannot be ruled out as a factor in the 5-HIAA results.
Literature
go back to reference Anderson AM, Bhondoekhan F, Curanovic D et al (2022) Higher soluble CD163 in blood is associated with significant depression symptoms in men with HIV. Journal of Acquired Immune Deficiency Syndromes (JAIDS) Anderson AM, Bhondoekhan F, Curanovic D et al (2022) Higher soluble CD163 in blood is associated with significant depression symptoms in men with HIV. Journal of Acquired Immune Deficiency Syndromes (JAIDS)
go back to reference Bailey RK, Patel M, Barker NC, Ali S, Jabeen S (2011) Major depressive disorder in the African American population. J Natl Med Assoc 103:548–557PubMed Bailey RK, Patel M, Barker NC, Ali S, Jabeen S (2011) Major depressive disorder in the African American population. J Natl Med Assoc 103:548–557PubMed
go back to reference Bejamini YHY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological) 257:289–300 Bejamini YHY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological) 257:289–300
go back to reference Bennett BA, Rusyniak DE, Hollingsworth CK (1995) HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 705:168–176CrossRefPubMed Bennett BA, Rusyniak DE, Hollingsworth CK (1995) HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 705:168–176CrossRefPubMed
go back to reference Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8:67–71CrossRefPubMed Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8:67–71CrossRefPubMed
go back to reference Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH (2003) Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28:339–347CrossRefPubMed Carpenter LL, Anderson GM, Siniscalchi JM, Chappell PB, Price LH (2003) Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. Neuropsychopharmacology 28:339–347CrossRefPubMed
go back to reference Cook JA, Burke-Miller JK, Steigman PJ et al (2018) Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav 22:3141–3154CrossRefPubMedPubMedCentral Cook JA, Burke-Miller JK, Steigman PJ et al (2018) Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav 22:3141–3154CrossRefPubMedPubMedCentral
go back to reference Cysique LA, Franklin D Jr, Abramson I et al (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 33:505–522CrossRefPubMedPubMedCentral Cysique LA, Franklin D Jr, Abramson I et al (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 33:505–522CrossRefPubMedPubMedCentral
go back to reference De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA (1993) Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 33:636–641CrossRefPubMed De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA (1993) Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 33:636–641CrossRefPubMed
go back to reference Do AN, Rosenberg ES, Sullivan PS et al (2014) Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE 9CrossRefPubMedPubMedCentral Do AN, Rosenberg ES, Sullivan PS et al (2014) Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS ONE 9CrossRefPubMedPubMedCentral
go back to reference Ellis RJ, Letendre SL, Atkinson JH et al (2020) Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. Brain Behav Immun Health 7CrossRefPubMedPubMedCentral Ellis RJ, Letendre SL, Atkinson JH et al (2020) Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIV. Brain Behav Immun Health 7CrossRefPubMedPubMedCentral
go back to reference Gallant J, Hsue PY, Shreay S, Meyer N (2017) Comorbidities among US patients with prevalent HIV infection-a trend analysis. J Infect Dis 216:1525–1533PubMed Gallant J, Hsue PY, Shreay S, Meyer N (2017) Comorbidities among US patients with prevalent HIV infection-a trend analysis. J Infect Dis 216:1525–1533PubMed
go back to reference Global Burden of Disease Study C (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800 Global Burden of Disease Study C (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800
go back to reference Group ISS, Lundgren JD, Babiker AG et al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373:795–807CrossRef Group ISS, Lundgren JD, Babiker AG et al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373:795–807CrossRef
go back to reference Heaton RK, Miller SW, Taylor MJ, Grant I (2004) Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted Europsycho-logical norms for African American and Caucasian adults scoring program Heaton RK, Miller SW, Taylor MJ, Grant I (2004) Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted Europsycho-logical norms for African American and Caucasian adults scoring program
go back to reference Horberg MA, Silverberg MJ, Hurley LB et al (2008) Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 47:384–390CrossRefPubMed Horberg MA, Silverberg MJ, Hurley LB et al (2008) Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 47:384–390CrossRefPubMed
go back to reference Ickovics JR, Hamburger ME, Vlahov D et al (2001) Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA, J Am Med Assoc 285:1466–1474CrossRef Ickovics JR, Hamburger ME, Vlahov D et al (2001) Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA, J Am Med Assoc 285:1466–1474CrossRef
go back to reference Jayamohananan H, Manoj Kumar MK (2019) T PA 5-HIAA as a potential biological marker for neurological and psychiatric disorders. Adv Pharm Bull 9:374–81 Jayamohananan H, Manoj Kumar MK (2019) T PA 5-HIAA as a potential biological marker for neurological and psychiatric disorders. Adv Pharm Bull 9:374–81
go back to reference Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB (2010) Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr 53:266–272CrossRefPubMedPubMedCentral Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB (2010) Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr 53:266–272CrossRefPubMedPubMedCentral
go back to reference Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993) Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psych 50:599–605 Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993) Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psych 50:599–605
go back to reference Kumar AM, Berger JR, Eisdorfer C, Fernandez JB, Goodkin K, Kumar M (2001) Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology 44:13–18CrossRefPubMed Kumar AM, Berger JR, Eisdorfer C, Fernandez JB, Goodkin K, Kumar M (2001) Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology 44:13–18CrossRefPubMed
go back to reference Kumar AM, Fernandez JB, Singer EJ et al (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:257–274CrossRefPubMedPubMedCentral Kumar AM, Fernandez JB, Singer EJ et al (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15:257–274CrossRefPubMedPubMedCentral
go back to reference Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28:406–409CrossRefPubMed Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28:406–409CrossRefPubMed
go back to reference Mitchell AJ, Vaze A, Rao S (2009) Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374:609–619CrossRefPubMed Mitchell AJ, Vaze A, Rao S (2009) Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374:609–619CrossRefPubMed
go back to reference Musinguzi K, Obuku A, Nakasujja N et al (2018) Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda. BMC Immunol 19:1CrossRefPubMedPubMedCentral Musinguzi K, Obuku A, Nakasujja N et al (2018) Association between major depressive disorder and pro-inflammatory cytokines and acute phase proteins among HIV-1 positive patients in Uganda. BMC Immunol 19:1CrossRefPubMedPubMedCentral
go back to reference Norcini Pala A, Steca P, Bagrodia R et al (2016) Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun 56:105–113CrossRefPubMed Norcini Pala A, Steca P, Bagrodia R et al (2016) Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun 56:105–113CrossRefPubMed
go back to reference Ogawa S, Tsuchimine S, Kunugi H (2018) Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: a meta-analysis of historic evidence. J Psychiatr Res 105:137–146CrossRefPubMed Ogawa S, Tsuchimine S, Kunugi H (2018) Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: a meta-analysis of historic evidence. J Psychiatr Res 105:137–146CrossRefPubMed
go back to reference Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288–295CrossRefPubMed Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288–295CrossRefPubMed
go back to reference Pence BW, Mills JC, Bengtson AM et al (2018) Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiat 75:379–385CrossRef Pence BW, Mills JC, Bengtson AM et al (2018) Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiat 75:379–385CrossRef
go back to reference Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC (2014) C-reactive protein and depression in persons with human immunodeficiency virus infection: the Positive Living with HIV (POLH) Study. Brain Behav Immun 42:89–95CrossRefPubMed Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC (2014) C-reactive protein and depression in persons with human immunodeficiency virus infection: the Positive Living with HIV (POLH) Study. Brain Behav Immun 42:89–95CrossRefPubMed
go back to reference Riolo SA, Nguyen TA, Greden JF, King CA (2005) Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health 95:998–1000CrossRefPubMedPubMedCentral Riolo SA, Nguyen TA, Greden JF, King CA (2005) Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health 95:998–1000CrossRefPubMedPubMedCentral
go back to reference Robertson K, Yosief S (2014) Neurocognitive assessment in the diagnosis of HIV-associated neurocognitive disorders. Semin Neurol 34:21–26CrossRefPubMed Robertson K, Yosief S (2014) Neurocognitive assessment in the diagnosis of HIV-associated neurocognitive disorders. Semin Neurol 34:21–26CrossRefPubMed
go back to reference Roy A, De Jong J, Linnoila M (1989) Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Arch Gen Psych 46:609–12 Roy A, De Jong J, Linnoila M (1989) Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Arch Gen Psych 46:609–12
go back to reference Saloner R, Cherner M, Grelotti DJ et al (2020) Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain Behav Immun 90:353–363CrossRefPubMedPubMedCentral Saloner R, Cherner M, Grelotti DJ et al (2020) Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain Behav Immun 90:353–363CrossRefPubMedPubMedCentral
go back to reference Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS (2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25:468–475CrossRefPubMed Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS (2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25:468–475CrossRefPubMed
go back to reference Scheller C, Sopper S, Jenuwein M et al (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 95:377–387CrossRefPubMed Scheller C, Sopper S, Jenuwein M et al (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 95:377–387CrossRefPubMed
go back to reference Shah S, Sinharay S, Matsuda K et al (2019) Potential mechanism for HIV-associated depression: upregulation of serotonin transporters in SIV-infected macaques detected by 11C-DASB PET. Front Psych 10:362CrossRef Shah S, Sinharay S, Matsuda K et al (2019) Potential mechanism for HIV-associated depression: upregulation of serotonin transporters in SIV-infected macaques detected by 11C-DASB PET. Front Psych 10:362CrossRef
go back to reference Sheline Y, Bardgett ME, Csernansky JG (1997) Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 17:11–14CrossRefPubMed Sheline Y, Bardgett ME, Csernansky JG (1997) Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 17:11–14CrossRefPubMed
go back to reference Sin NL, DiMatteo MR (2014) Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med 47:259–269CrossRefPubMed Sin NL, DiMatteo MR (2014) Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med 47:259–269CrossRefPubMed
go back to reference Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA (2012) Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 48:66–78CrossRefPubMedPubMedCentral Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA (2012) Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 48:66–78CrossRefPubMedPubMedCentral
go back to reference Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J et al (2006) CD4+ count-guided interruption of antiretroviral treatment. The New England J Med 355:2283–96 Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J et al (2006) CD4+ count-guided interruption of antiretroviral treatment. The New England J Med 355:2283–96
go back to reference Vlassova N, Angelino AF, Treisman GJ (2009) Update on mental health issues in patients with HIV infection. Curr Infect Dis Rep 11:163–169CrossRefPubMed Vlassova N, Angelino AF, Treisman GJ (2009) Update on mental health issues in patients with HIV infection. Curr Infect Dis Rep 11:163–169CrossRefPubMed
go back to reference Williams DR, Gonzalez HM, Neighbors H et al (2007) Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 64:305–315CrossRefPubMed Williams DR, Gonzalez HM, Neighbors H et al (2007) Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 64:305–315CrossRefPubMed
Metadata
Title
Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression
Authors
Rong Fu
Hyder Jinnah
J. Lucas Mckay
Andrew H. Miller
Jennifer C. Felger
Eugene W. Farber
Sanjay Sharma
Neil Whicker
Raeanne C. Moore
Donald Franklin
Scott L. Letendre
Albert M. Anderson
Publication date
08-06-2023
Publisher
Springer International Publishing
Published in
Journal of NeuroVirology / Issue 4/2023
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI
https://doi.org/10.1007/s13365-023-01142-2

Other articles of this Issue 4/2023

Journal of NeuroVirology 4/2023 Go to the issue